The Use of Type I and Type III Injectable Human Collagen for Dermal Fill: 10 Years of Clinical Experience in China

摘要

This article reports preclinical and clinical experience with a type I and type III injectable human collagen product derived from human sources (containing type I and type III collagen in a proportion of 44:56) utilized as a dermal filler. The preclinical study involves experiments characterizing the histological changes observed after type I and type III injectable human collagen injection in rats. The clinical trial is a study of 123 patients treated with type I and type III injectable human collagen for pitting skin deficiencies including furrow, superficial scar, and superficial atrophy. Histological observations from the preclinical study revealed that type I and type III injectable human collagen persisted for at least a year. The clinical trial showed that most patients were satisfied with the results, and a rating of excellent or good was achieved 90.2% of the time. The positive results lasted about 9 months after the first injection, 12 months after the second injection, and 18 months after the third injection. Reported side effects were slight redness and discomfort at or near the injection site. Type I and type III injectable human collagen is a safe and reliable biomaterial that can easily be used for soft tissue augmentation.